Pharmacokinetics of firocoxib after intravenous administration of multiple consecutive doses in neonatal foals

The purpose of this study was to determine the pharmacokinetic profile of intravenous firocoxib in neonatal foals. Six healthy foals were administered 0.09 mg/kg firocoxib intravenously once a day for 7 days. Blood was collected for plasma firocoxib analysis using high-performance liquid chromatography with fluorescence detection at times 0 (day 1 of study only) and 0.08, 0.25, 1, 2, 4, 6, 8, 16 and 24 hr on dose numbers 1, 5 and 7. Blood was also collected immediately prior to doses 3, 4, 5 and 7. Final samples were collected at 36, 48, 72 and 96 hr following the final dose. Noncompartmental analysis using the trapezoidal method with linear interpolation revealed a moderate half-life (15.9 ± 9.1 hr) with a large volume of distribution at steady state (1.79 ± 0.57 L/kg) and a clearance (96.0 ± 59.2 ml h-1  kg-1 ) that was more rapid than that observed in adult horses.

[1]  B. Kukanich,et al.  Pharmacokinetics of oral terbinafine in adult horses , 2017, Journal of veterinary pharmacology and therapeutics.

[2]  A. Blikslager,et al.  Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. , 2015, Journal of veterinary pharmacology and therapeutics.

[3]  S. Stanley,et al.  Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses. , 2014, Equine veterinary journal.

[4]  Jennifer L Davis,et al.  Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals. , 2014, Journal of veterinary pharmacology and therapeutics.

[5]  M. Krockenberger,et al.  In vitro hepatic microsomal metabolism of meloxicam in koalas (Phascolarctos cinereus), brushtail possums (Trichosurus vulpecula), ringtail possums (Pseudocheirus peregrinus), rats (Rattus norvegicus) and dogs (Canis lupus familiaris). , 2014, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[6]  R. Boston,et al.  Pharmacokinetics and safety of oral administration of meloxicam to foals. , 2013, Journal of veterinary internal medicine.

[7]  R. Boston,et al.  Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses. , 2012, American journal of veterinary research.

[8]  S. Stanley,et al.  Distribution of flunixin meglumine and firocoxib into aqueous humor of horses. , 2011, Journal of veterinary internal medicine.

[9]  P. Smith,et al.  Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum binding , 2011, Biopharmaceutics & drug disposition.

[10]  P. Hanson,et al.  Field Trial Validation of the Efficacy and Acceptability of Firocoxib, a Highly Selective Cox-2 Inhibitor, in a Group of 96 Lame Horses , 2010 .

[11]  A. Blikslager,et al.  Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum , 2009 .

[12]  M. Hedeland,et al.  A mass spectrometric study on meloxicam metabolism in horses and the fungus Cunninghamella elegans, and the relevance of this microbial system as a model of drug metabolism in the horse. , 2009, Journal of mass spectrometry : JMS.

[13]  S. McClure,et al.  Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. , 2008, American journal of veterinary research.

[14]  T. Malinski,et al.  Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  P. Hanson,et al.  Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. , 2007, Journal of veterinary pharmacology and therapeutics.

[16]  D. Little,et al.  Cyclooxygenase (COX) inhibitors and the intestine. , 2007, Journal of veterinary internal medicine.

[17]  S. Valberg,et al.  Suspected Immune‐Mediated Myositis in Horses , 2007 .

[18]  R. Linke,et al.  Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis , 2004, Journal of clinical pharmacology.

[19]  C. Berde,et al.  Analgesics for the treatment of pain in children. , 2002, The New England journal of medicine.

[20]  M. Relling,et al.  Human cytochrome P450 maximal activities in pediatric versus adult liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  R. Sams,et al.  Pharmacokinetics of ketoprofen in healthy foals less than twenty-four hours old. , 1998, American journal of veterinary research.

[22]  R. Sams,et al.  Pharmacokinetics of flunixin meglumine in healthy foals less than twenty-four hours old. , 1996, American Journal of Veterinary Research.

[23]  R. Sams,et al.  Pharmacokinetics of phenylbutazone in neonatal foals. , 1993, American journal of veterinary research.

[24]  Semrad Sd,et al.  Pharmacokinetics of and serum thromboxane suppression by flunixin meglumine in healthy foals during the first month of life. , 1993 .

[25]  A. Warner.  Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. , 1986, Clinical chemistry.

[26]  P. Gavin,et al.  Phenylbutazone toxicosis in the foal. , 1983, American journal of veterinary research.

[27]  S. Budsberg,et al.  Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses. , 2014, Equine veterinary journal.

[28]  B. Samuelsson,et al.  An Elucidation of the Arachidonic Acid Cascade , 2012, Drugs.

[29]  M. Doucet,et al.  Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. , 2008, Journal of the American Veterinary Medical Association.

[30]  S. Valberg,et al.  Suspected immune-mediated myositis in horses. , 2007, Journal of Veterinary Internal Medicine.

[31]  P. Toutain,et al.  Plasma clearance. , 2004, Journal of veterinary pharmacology and therapeutics.

[32]  T. Hedner,et al.  COX-2-Specific Inhibitors – the Emergence of a New Class of Analgesic and Anti-inflammatory Drugs , 2000, Clinical Rheumatology.

[33]  C. Macallister,et al.  Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. , 1993, Journal of the American Veterinary Medical Association.

[34]  J. Traub-Dargatz,et al.  Chronic flunixin meglumine therapy in foals. , 1988, American journal of veterinary research.

[35]  B. Samuelsson.  An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. , 1987, Drugs.

[36]  G. Fülgraff.  Prostaglandins and inflammation. , 1974, Advances in clinical pharmacology.